Sports performance research ↗ · Military & occupational performance ↗
Chlodantane, Cyclontane & the ADK program ↗
MOLEKUL / RESEARCH COVERAGEActoprotector and nootropic evidence
Comparative studies of compounds developed for physical work capacity or cognitive function, including Bemitil, Bromantane and racetams.
Findings from selected studies
- Endurance after six hours of exertion
In an eight-group study of 78 volunteers, participants retained 86.2% of baseline dynamic endurance with Bemitil and 84.3% with Pirabel, compared with 68.1% with placebo. Two publications describe this experiment.
Browse study findings by subject ↓
Updated 2 October 2026. Publication records are not independent-trial counts. Translations, abridged reprints and overlapping cohorts are identified where possible. “Full text available” describes access; review depth is shown separately.
Bromantane ↗
Clinical methods and attrition recovered
The Neznamov paper describes 15 patients per arm, with only seven placebo participants completing. A separate 40-patient report is now linked. These reports require cohort-overlap checks.
What remains unresolved
The mental-fatigue, heat, gas and altitude reports cover different settings. The 2009 clinical publications may share participants.
Bemitil ↗
Combination-source links repaired
The Trekrezan–Metaprot animal report and Bromitil pharmacokinetic source are linked. The Pirabel program now has separate experiment descriptions.
What remains unresolved
The 1991 voyage scan has been checked: 298 participants, with detailed testing in a 20-person subset; reported outcomes, regimen and adverse reactions are now transcribed. Allocation and ambiguous morbidity wording still require care. The 130-patient asthenia paper and 1984/1993/1994 proceedings remain retrieval targets.
Kim: hypoxia comparison
48 healthy men aged 20–28 · Drug and placebo exposures separated by 2–3 weeks; four baseline-matched groups
Measures: Laboratory mental and physical performance. Transcription loses some denominators; allocation order and washout adequacy remain unresolved.
Program source ↗Kim: human pharmacokinetics
18 healthy men aged 21–25; three groups of six · Single-exposure comparison of combination and individual components
Measures: Blood concentration time course. Pharmacokinetics does not establish efficacy or clinical synergy.
Program source ↗Pirabel: prolonged physical work
78 volunteers aged 18–25; eight baseline-matched groups · Described as double-blind; six-hour cyclic physical-work model
Measures: Dynamic work, endurance and recovery measures. Randomization unconfirmed; no piracetam-only arm. Separate from the subsequent 20-man Bemitil/Sydnocarb experiment.
Program source ↗Trekrezan ↗
Duplicate cold-study record consolidated
The two records for PMID 18383733 now resolve to one publication. The 75-man cold report remains distinct from animal immune-metabolism work.
What remains unresolved
The Ganapolsky dissertation describes a broader program. Group sizes in the cold studies and participant overlap between the 2007 and 2008 reports remain uncertain.
B-300 ↗
Separate experiments and source format identified
Mental-fatigue, escalation and environmental tests are listed separately below. A transcription and later institutional history do not constitute independent replication.
What remains unresolved
The available description of Elistratov’s dissertation leaves allocation, complete results and safety follow-up unclear.
B-300: mental-fatigue comparison
30 active-treatment participants and 10 placebo · Post-educational-workload comparison
Measures: Cognitive tasks and self-rated state. Transcribed summary; allocation, complete baseline tables and missing outcomes require original thesis.
Program source ↗B-300: activation-versus-accuracy experiment
34 participants in 12/12/10 groups · Separate escalation comparison
Measures: Activation and operator errors. Higher activation did not mean greater accuracy. Not pooled with the fatigue experiment.
Program source ↗B-300: environmental comparisons
Small groups; arm-by-environment denominators require original verification · Cold, heat and simulated-altitude experiments
Measures: Physical and mental task performance. Historical controls and repeated testing; not a single uniform trial or proof of operational protection.
Program source ↗Pirabel ↗
Program and experiment boundaries expanded
The recovered monograph comparison and Kim dissertation transcription are linked. Human pharmacokinetics, training and environmental performance are separated.
What remains unresolved
The thesis and experiment publications may include volunteers from the 78-person monograph series.
Kim: hypoxia comparison
48 healthy men aged 20–28 · Drug and placebo exposures separated by 2–3 weeks; four baseline-matched groups
Measures: Laboratory mental and physical performance. Transcription loses some denominators; allocation order and washout adequacy remain unresolved.
Program source ↗Kim: visuomotor learning
40 inexperienced operators; five groups of eight · Described as randomized and double-blind
Measures: Time maintaining a tracking signal in its target area. Small groups and practice effects; not an operational accident or fatigue-safety study.
Program source ↗Kim: human pharmacokinetics
18 healthy men aged 21–25; three groups of six · Single-exposure comparison of combination and individual components
Measures: Blood concentration time course. Pharmacokinetics does not establish efficacy or clinical synergy.
Program source ↗Pirabel: prolonged physical work
78 volunteers aged 18–25; eight baseline-matched groups · Described as double-blind; six-hour cyclic physical-work model
Measures: Dynamic work, endurance and recovery measures. Randomization unconfirmed; no piracetam-only arm. Separate from the subsequent 20-man Bemitil/Sydnocarb experiment.
Program source ↗Bromitil ↗
Previously empty source trail populated
The Krasnykh dissertation transcription identifies the combined-tablet pharmacokinetic research. Animal exposure changes are not evidence of clinical synergy.
What remains unresolved
The dissertation and formulation specification are cited. Human benefit and the safety of the combination remain uncertain.
Etomerzol ↗
Original experimental publication added
The 2003 publisher record documents rat hypoxia and in-vitro antioxidant work. This supplies a traceable experimental source rather than a name alone.
What remains unresolved
The 2019 monograph pairs etomerzol and tomerzol on p. 266. Earlier reports leave questions about preparation identity, methods and replication. Human benefit remains unestablished.
Noopept ↗
Clinical records and environmental methods expanded
The missing Noopept–piracetam publications and encephalopathy citation are linked. The environmental PDF identifies historical controls, small groups and experimental formulations.
What remains unresolved
The original clinical comparisons are unavailable in full. The translation and EEG reports may overlap. Some environmental-exposure table values and arm sizes are unclear in the available copy.
Phenotropil ↗
Full-text attrition changes interpretation
The epilepsy paper reports 32 adverse-event discontinuations. TRIUMPH analyzed 1,170 of 2,029 participants after 859 protocol/documentation exclusions.
What remains unresolved
Complete outcome-table, missing-data and funding appraisal; retrieve original toxicology and bioequivalence records. Racemate and isolated enantiomers remain distinct.
Piracetam ↗
Condition-specific review and original trials added
Acute-stroke review, memory-training trial and post-stroke rehabilitation trial now complement the older memory literature. Noopept comparisons are shared sources, not new independent trials.
What remains unresolved
The original reports would clarify methods, harms and overlap with reviews. The stroke studies enrolled patients, leaving effects on cognition in healthy workers unresolved.
Kim: hypoxia comparison
48 healthy men aged 20–28 · Drug and placebo exposures separated by 2–3 weeks; four baseline-matched groups
Measures: Laboratory mental and physical performance. Transcription loses some denominators; allocation order and washout adequacy remain unresolved.
Program source ↗Kim: visuomotor learning
40 inexperienced operators; five groups of eight · Described as randomized and double-blind
Measures: Time maintaining a tracking signal in its target area. Small groups and practice effects; not an operational accident or fatigue-safety study.
Program source ↗Kim: human pharmacokinetics
18 healthy men aged 21–25; three groups of six · Single-exposure comparison of combination and individual components
Measures: Blood concentration time course. Pharmacokinetics does not establish efficacy or clinical synergy.
Program source ↗Pirabel: prolonged physical work
78 volunteers aged 18–25; eight baseline-matched groups · Described as double-blind; six-hour cyclic physical-work model
Measures: Dynamic work, endurance and recovery measures. Randomization unconfirmed; no piracetam-only arm. Separate from the subsequent 20-man Bemitil/Sydnocarb experiment.
Program source ↗Picamilon ↗
2024/2025 publisher texts recovered
Both 2024 reports and the 2025 study are linked with design and analysis-population details. Possible overlap is flagged; no pooled enrollment is presented.
What remains unresolved
Resolve participant overlap with authors or recruitment records; recover Ufa proceedings and swimmer dissertation. A 2011 swimmer PDF is linked; subgroup denominators and cohort overlap remain unresolved.
Semax ↗
Clinical comparison boundaries clarified
The acute-stroke abstract specifies 30 adjunctive-treatment patients and 80 conventional-care controls. Clinical comparisons remain separate from healthy-volunteer imaging.
What remains unresolved
The stroke and optic-nerve reports leave allocation, attrition and adverse events unclear. Imaging changes alone do not establish cognitive benefit or occupational safety.
Selank ↗
Additional clinical comparison and source discrepancy added
The 70-patient adjunctive phenazepam report is linked. The shortened 2008 reprint conflicts with the indexed abstract on treatment-arm sizes.
What remains unresolved
The accessible 2008 report leaves group sizes, blinding and allocation unclear. Similarity to medazepam does not establish equivalence.
Bibliography and original-document links ↗
Study findings by subject
52 source records
2026 · Comparison in people
Mexidol and cognitive testing in 90 older adults with chronic cerebral ischemia
At three months, median MMSE was 27 vs 26 points. Schulte test time fell by 8 vs 2 seconds with add-on Mexidol and standard care alone, respectively.
2026 · Comparison in people
Mexidol with robotic rehabilitation in 47 children with spastic cerebral palsy
The authors reported improvements of 37.6–58.7% across motor measures with Mexidol plus robotic rehabilitation, versus 24–39% with rehabilitation alone.
2026 · Review of earlier studies
Clinical efficacy of omberacetam in adults with cognitive impairment: a systematic review
The authors report cognitive improvements across earlier clinical studies, with MMSE changes ranging from +0.6 to +3.5 points. They used a qualitative synthesis and did not perform a meta-analysis because the studies differed substantially.
2026 · Review of earlier studies
Potential uses of omberacetam in the early prevention and management of cognitive impairment: expert-council resolution
The council discusses possible use within broader care for early cognitive impairment and vascular risk, and calls for further multicenter randomized studies.
2024 · Comparison in people
Evaluation of Noopept therapy in patients with cognitive impairment and cardiovascular disease
The Noopept group reached a median MoCA score of 26 [26;27], improving by 2 [1;3] points. Reported Schulte-task times were 45.3 [38.5;50.5] seconds versus 55.0 [47.5;59.8] seconds in controls; anxiety and depression scores also improved.
2022 · Randomized study in people
Nootropic drugs in patients with non-dementia vascular cognitive impairment
The abstract reports a MoCA increase from 19.8 to 23.3 in the omberacetam group at day 45. At the later assessment, the score remained 0.8 points above baseline (p=0.061), which does not establish a persistent statistically significant effect.
2004 · Laboratory analysis
Interspecies differences of Noopept pharmacokinetics
Elimination slowed from rats to rabbits to humans, with substantial individual variability in people. The abstract reports no metabolites detected in human plasma, potentially because concentrations were low.
2018 · Animal research
Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats
Cycloprolylglycine was found in rat plasma and brain and had a pharmacokinetic profile different from the parent drug. The paper relates these findings to memory-associated pharmacology.
2025 · Laboratory analysis
Physicochemical and structural analysis of Noopept
A Polish/Greek collaboration used thermal analysis, spectroscopy, diffraction and computational methods to characterize Noopept and screen for polymorphism.
2025 · Laboratory analysis
Nootropic product market surveillance by 12 official medicines control laboratories
Official laboratories identified 34 different substances across the program, including Noopept in bulk raw material. The report documents product-market concerns rather than a treatment trial.
2026 · Animal research
Effects of Piracetam and Hyperbaric Oxygen on Histopathological and Circulating Biochemical Responses Following Sciatic Nerve Crush Injury in Rats
After 14 days, piracetam, hyperbaric oxygen and their combination did not significantly improve axonal continuity, myelin regeneration or capillary formation. Piracetam increased fibroblast density and inflammatory-cell infiltration; selected circulating biochemical markers also changed. These early tissue and biomarker changes did not establish functional nerve recovery.
Animals and follow-up · 40 rats; four groups of 10; 14 days
2026 · Laboratory analysis
3D electron diffraction reveals piracetam Form VI two decades after its computational prediction
Three-dimensional electron diffraction resolved piracetam crystal Form VI, previously predicted computationally. Free-energy calculations place it among polymorphs accessible under ambient conditions. This is a solid-state chemistry result, not a trial of cognitive effects.
2026 · Observational study
Oral Glutamatergic Modulation With Dextromethorphan and Piracetam for Refractory Bipolar Disorder With Obsessive-Compulsive Disorder: Three Consecutive Cases From Routine Practice
A February 2026 clinical communication describes dextromethorphan with piracetam in three consecutive cases. The indexed record does not provide an abstract; doses, individual outcomes and adverse events have not been extracted.
2008 · Comparison in people
A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin
This clinical publication compared Noopept and piracetam for cognitive impairment after vascular or traumatic brain disease. The indexed citation supplies no arm sizes or cognitive scores.
2009 · Comparison in people
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin
This publication compared Noopept and piracetam in patients with mild cognitive impairment of vascular or traumatic origin. The indexed citation gives no numerical comparison. Its title and authors overlap with the 2008 publication.
2009 · Comparison in people
Efficacy of noopept in discirculatory encephalopathy
The paper examined Noopept in patients described as having discirculatory encephalopathy, a historical term for chronic cerebrovascular disease. The indexed citation gives no treatment outcomes.
1976 · Randomized study in people
Increase in the power of human memory in normal man through the use of drugs
The double-blind verbal-learning experiment reported no effect at seven days and an improvement at fourteen days. This describes one experiment, not a universal onset schedule.
Daily piracetam amount · 4.8 g · Calculated from the printed capsule schedule
2024 · Review of earlier studies
Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis
The 2024 meta-analysis did not establish a statistically significant pooled memory benefit: SMD 0.75, 95% CI −0.19 to 1.69; p=0.12; I²=96%.
2002 · Review of earlier studies
Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Reported a favorable pooled clinical global impression of change. This differs from the memory-specific outcome in the 2024 analysis.
1989 · Animal research
The new cerebrovascular preparation pikamilon
Early cerebrovascular experiments reported changes in cerebral blood flow and experimentally disturbed vascular responses.
2000 · Animal research
Effects of pikamilon on the brain water-electrolyte balance and in models of responses to the noise and vibration exposure, and their combination with motion sickness
Noise, vibration and combined motion-sickness models were assessed using brain impedance measures. The authors reported attenuation of water–electrolyte disturbances. This was not a study in sailors.
2005 · Animal research
Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon
Receptor-blockade experiments found different effects of bicuculline and picrotoxin on Picamilon-associated cerebrovascular responses. This does not establish direct receptor binding.
2006 · Animal research
The effect of hypokinesia on depression and on the central GABA-A receptor complexes in the rat brain
Behavioral and receptor measurements suggested a tendency toward recovery with Picamilon or piracetam. Animal behavioral endpoints are not clinical depression or maritime performance outcomes.
2010 · Animal research
Effect of nootropes on quantitative changes in the rat cerebral cortex GABA(A) receptor complexes under experimental hypokinesia conditions
Shorter schedules showed no visible receptor-count change; the longer schedule showed a tendency toward restoration with Picamilon. Findings were schedule-dependent.
2009 · Comparison in people
Effects of aminalon, fenibut, and picamilon on the typological parameters of cerebral hemodynamics in swimmers with dysadaptation syndrome
A swimmer study reported changes in cerebral circulation after four weeks of Aminalon, Phenibut or Picamilon; Picamilon did not show the described venous-outflow improvement in the hypokinetic subgroup.
2010 · Laboratory analysis
Determination of picamilon concentration in human plasma by liquid chromatography-tandem mass spectrometry
Validated an LC-MS/MS assay and applied it to human pharmacokinetics. Plasma detection does not establish brain delivery or cognitive benefit.
Linear analyte range · 1–5,000 ng/mL
2023 · Lab research
Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets
Picamilon showed weak or no binding at 10 μM across the tested panel. This does not exclude other targets, metabolites or effects at other concentrations.
2024 · Randomized study in people
Integrative assessment of the effectiveness and safety of outpatient use of Picamilon
Cognitive scores and sleep questionnaires improved during two active Picamilon schedules. There was no untreated or placebo group.
MoCA cognitive score · 24.9 → 26.5 → 28.3 points · Pooled active-treatment sample; the abstract does not map all three quoted values to specific visits · Reported serial assessments · p=0.022 and p<0.001 as reported
2003 · Animal research
Preclinical prognosis of pyracetam and picamilon safety based on acute toxicity data
Picamilon and Piracetam differed in acute toxicity in rats but showed approximately similar ranges of activity on the study’s functional and behavioral measures.
1983 · Animal research
Pharmacological characteristics of a new phenyl analog of piracetam—4-phenylpiracetam
The abstract describes operant-behavior, amnesia and other neuropharmacological findings for 4-phenylpiracetam compared with related compounds.
1987 · Animal research
Pharmacological characterization of Carphedon
This conference report attributes synthesis to Perecalin’s group at the Herzen Leningrad Pedagogical Institute. It reports longer swimming at 2°C and 25°C, but shorter swimming at 45°C.
2011 · Animal research
Investigation into Stereoselective Pharmacological Activity of Phenotropil
The study compares the pharmacological activity of different stereochemical forms, emphasizing why results for an isolated enantiomer should not automatically be assigned to the racemate.
2008 · Study involving people
Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin
A Noopept report described increased alpha/beta EEG power and reduced delta power in patients with vascular or traumatic brain disorders; it supplies no numerical clinical response rate.
2008 · Animal research
Noopept stimulates the expression of NGF and BDNF in rat hippocampus
In rats, one Noopept administration raised hippocampal NGF and BDNF mRNA, while both transcripts fell in the cerebral cortex. After 28 days, the authors reported a stronger hippocampal response.
2016 · Lab research
Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept
Noopept increased HIF-1 reporter activity in this experimental system. Docking suggested a possible interaction with prolyl hydroxylase 2.
2000 · Lab research
Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress
GVS-111 showed protective effects in oxygen/glucose deprivation and glutamate/oxidative-stress models; piracetam did not attenuate glutamate toxicity in this experiment.
2001 · Animal research
Behavioral and electrophysiological analysis of the choline-positive effect of nootropic dipeptide acylproline (GVS-111)
Behavioral and electrophysiological findings suggested involvement of muscarinic and nicotinic signaling in the response to GVS-111.
2021 · Comparison in people
Dilept versus risperidone in a 28-day psychiatric comparison
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
2017 · Comparison in people
Dose-ranging cognitive report from the 25-patient Dilept pilot
The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
2009 · Animal research
Dilept formulation and metabolite exposure in rats
Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.
2026 · Randomized study in people
Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
2007 · Animal research
CCK-4 dipeptide analogue design: opposite behavioral effects of L- and D-tryptophan derivatives
L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.
1991 · Randomized study in people
Dose-ranging CCK-4 panic-challenge study in healthy volunteers
Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.
CCK-4 panic incidence · 11% / 17% / 47% across increasing doses; 0 with placebo
2025 · Observational study
Psychosomatic features of anxiety and depressive disorders
The authors report improvement in anxiety-related and somatic symptoms during Selank treatment. The accessible publisher abstract does not quantify a controlled treatment effect.
2015 · Comparison in people
Optimization of the treatment of anxiety disorders with selank
The authors report earlier symptom improvement and fewer unwanted effects with adjunctive Selank. Both groups received phenazepam.
2000 · Controlled study in people
Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease
A three-group optic-nerve report described faster visual recovery when Semax was added to neurotrophic and anti-inflammatory care, without numerical visual-acuity or field changes in its abstract.
2008 · Randomized study in people
Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia
The authors report similar anxiety changes with the two treatments and assess serum enkephalin metabolism.
2014 · Comparison in people
A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders
At day 14 the anxiety subscore fell 26.3% with Selank vs 55% with phenazepam. A week after stopping therapy, the paper reported 17 vs 9 responders (p=0.037).
2001 · Lab research
Semax and Selank inhibit enkephalin-degrading enzymes from human serum
Both peptides and certain fragments inhibited peptide-degrading enzymes in laboratory assays.
Semax IC50 · 10 microM
2003 · Animal research
Selank and short peptides of the tuftsin family in regulation of adaptive behavior in stress
The experiments compare behavior across structurally related peptides and emotional-reactivity groups.
2016 · Animal research
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
The study reports changes in neurotransmission-related gene expression after Selank.
Changed genes at one hour · 45
2018 · Lab research
Peptide-based Anxiolytics: Molecular Aspects of Heptapeptide Selank Biological Activity
The authors examine GABA-binding modulation as a possible mechanistic explanation.